USD29.85
Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling - MM+M - Medical Marketing and Media Color:Crimson blockBR https://www.frontiersin.org/files/Articles/402374/xml-images/fphar-09-01162-g0001.webp Starting with a lower dose (such as 500mg once or twice daily) and gradually increasing may improve tolerability
USD29.85
USD26.51
USD24.18
USD20.51
USD28.34
USD22.39